About Us

Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation. More than 100 million Americans suffer from chronic pain. Existing therapeutics for chronic pain based upon opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are inadequate in addressing patient and physician needs, as well as a regulatory issue for the FDA. Use of these existing medicines presents significant safety, tolerability, abuse and addiction concerns that limit use. A major unmet medical need is an effective therapeutic for chronic pain that is devoid of both addictive potential and abuse liability. Algomedix has discovered and is developing a novel non-opiod drug that solves these problems. The estimated market for this potential first-in-class drug in the primary indication is estimated > $1 billion.